Guggenheim analyst Brad Canino reiterated a Buy rating and $26.00 price target on Relay Therapeutics (NASDAQ: RLAY)The analyst comments: “RLAY ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE